Practice and principle of traditional Chinese medicine for the prevention and treatment of COVID-19

被引:0
作者
Linhua Zhao
Chuanxi Tian
Yingying Yang
Huifang Guan
Yu Wei
Yuxin Zhang
Xiaomin Kang
Ling Zhou
Qingwei Li
Jing Ma
Li Wan
Yujiao Zheng
Xiaolin Tong
机构
[1] China Academy of Chinese Medical Sciences,Institute of Metabolic Diseases, Guang’anmen Hospital
[2] Beijing University of Chinese Medicine,National Center for Integrative Medicine
[3] China-Japan Friendship Hospital,College of Traditional Chinese Medicine
[4] Changchun University of Chinese Medicine,College of Traditional Chinese Medicine
[5] Anhui University of Chinese Medicine,undefined
来源
Frontiers of Medicine | 2023年 / 17卷
关键词
traditional Chinese medicine; COVID-19; SARS-CoV-2; clinical evidence-based study; mechanism; integrated traditional Chinese and Western medicine;
D O I
暂无
中图分类号
学科分类号
摘要
Traditional Chinese medicine (TCM) has played an important role in the prevention and treatment of Coronavirus disease 2019 (COVID-19) epidemic in China. The integration of Chinese and Western medicine is an important feature of Chinese COVID-19 prevention and treatment. According to a series of evidence-based studies, TCM can reduce the infection rate of severe acute respiratory syndrome coronavirus 2 in high-risk groups. For patients with mild and moderate forms of COVID-19, TCM can relieve the related signs and symptoms, shorten the period of nucleic-acid negative conversion, and reduce conversion rate to the severe form of the disease. For COVID-19 patients with severe and critical illnesses, TCM can improve inflammatory indicators and blood oxygen saturation, shorten the hospital stay, and reduce the mortality rate. During recovery, TCM can improve patients’ symptoms, promote organ function recovery, boost the quality of patients’ life, and reduce the nucleic-acid repositive conversion rate. A series of mechanism research studies revealed that capability of TCM to treat COVID-19 through antiviral and anti-inflammatory effects, immune regulation, and protection of organ function via a multicomponent, multitarget, and multipathway approach.
引用
收藏
页码:1014 / 1029
页数:15
相关论文
共 1108 条
[1]  
Xu Z(2020)Pathological findings of COVID-19 associated with acute respiratory distress syndrome Lancet Respir Med 8 420-422
[2]  
Shi L(2021)Understanding COVID-19 in Wuhan from the perspective of cold-dampness: clinical evidences and mechanisms Front Med (Lausanne) 8 617659-472
[3]  
Wang Y(2023)Effect of Lianhua Qingwen capsules on the positive rate of COVID-19 close contacts: a retrospective analysis of a large-scale population-based cohort study Phytomedicine 112 154690-3198
[4]  
Zhang J(2022)Jinhua Qinggan granules for non–hospitalized COVID-19 patients: a double–blind, placebo-controlled, and randomized controlled trial Front Med (Lausanne) 9 928468-1098
[5]  
Huang L(2020)Effect of Jinhua Qinggan granules on novel coronavirus pneumonia in patients J Tradit Chin Med 40 467-759
[6]  
Zhang C(2022)Initial observations of Jinhua Qinggan Granules, a Chinese medicine, in the mitigation of hospitalization and mortality in high–risk elderly with COVID-19 infection: a retrospective study in an old age home in Hong Kong Front Med (Lausanne) 9 948149-1092
[7]  
Liu S(2020)Real-world clinical study of traditional Chinese medicine treatment for 749 patients with coronavirus disease 2019 Chin J Tradit Chin Med Pharm (Zhonghua Zhong Yi Yao Za Zhi) 35 3194-1153
[8]  
Zhao P(2020)Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: a cohort study Pharmacol Res 161 105127-761
[9]  
Liu H(2022)Timely treatment and higher compliance to traditional Chinese medicine: new influencing factors for reducing severe COVID-19 based on retrospective cohorts in 2020 and 2021 Pharmacol Res 178 106174-246
[10]  
Zhu L(2021)Clinical efficacy evaluation of Xuanfei-Baidu granules in the treatment of novel coronavirus pneumonia infected with Omicron strain Tianjin J Tradit Chin Med (Tianjin Zhong Yi Yao) 39 1093-7478